Abstract: Pharmaceutical compositions comprising a protein serum amyloid P component (SAP) capable of binding viruses, especially myxovirus, e.g. influenza viruses and thereby preventing the transmission and infection with such viruses. Preferred is mucosal administration, e.g. SAP incorporated in a nose spray or nose drops. Also provided is a method for measuring the binding of SAP to the hemagglutinin of the prevailing influenza virus subtype and strain.
Type:
Grant
Filed:
July 24, 1998
Date of Patent:
June 18, 2002
Assignee:
Profylakse Aps
Inventors:
Sven-Erik Svehang, Ellen Holm Nielsen, Ove Andersen
© 2026 Justia
